FGFR1 and neoplasm: Extending our previous work and reports from other laboratories (Devilard et al, 2006; Sahadevan et al, 2007), we further validated the association of FGFR1 overexpression with CRPC and its impact on clinical outcome: (1) increased risk of developing CRPC with shorter time to relapse when FGFR1 expression is elevated in HN tumours, (2) higher levels in CR tumours when compared with HNPC, and (3) shorter time to death for CRPC with elevated FGFR expression.